Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Carcinoma, Non-Small-Cell Lung 4Breast Neoplasms 3Parkinson Disease 4, Autosomal Dominant Lewy Body 2Esophageal Neoplasms 2Urinary Bladder Neoplasms 1Ureteral Neoplasms 1Ovarian Neoplasms 1Metastatic Hormone-sensitive Prostate Cancer 1Metastatic Castration Resistant Prostate Cancer 1Fallopian Tube Neoplasms 1Carcinoma, Ovarian Epithelial 1

Interventions

pembrolizumab 3Paclitaxel 2Nivolumab 2Docetaxel 2ulixertinib 1trastuzumab biosimilar HLX02 1trametinib 1sapanisertib 1sacituzumab govitecan 1relatlimab 1pertuzumab 1palbociclib 1osimertinib 1omipalisib 1larotrectinib 1ipatasertib 1erdafitinib 1defactinib 1dabrafenib 1copanlisib 1capivasertib 1binimetinib 1adavosertib 1X-Rays 1Trastuzumab 1Sunitinib 1Specimen Handling 1PF-05280014 1Ontruzant 1Ogivri 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has announcements × Esophageal Neoplasms × Docetaxel × Clear all
NCT02564263 2023-03-13

KEYNOTE-181

Merck Sharp & Dohme LLC

Phase 3 Completed
628 enrolled 27 charts 1 FDA
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Neoplasms

NCT02569242 2022-07-06

Study of Nivolumab in Unresectable Advanced or Recurrent Esophageal Cancer

Ono Pharmaceutical Co., Ltd.

Phase 3 Completed
419 enrolled 20 charts 1 FDA
Gastrointestinal

Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡